Validation of analytical methods for quantification of a pentasaccharide biomarker in efficacy assessment of AVV treatment for GM1 gangliosidosis

点击翻译按钮获取中文摘要

PROJECT SUMMARY/ABSTRACT GM1-gangliosidosis is a rare, fatal, neurodegenerative genetic disease caused by the deficiency of β- galactosidase enzyme activity and characterized clinically by a wide range of variable neurovisceral, ophthalmological and dysmorphic features. There are currently no effective therapies for GM1-gangliosidosis and only symptomatic treatments are available. In preclinical models, adeno-associated viral (AAV) gene therapy that restores the β-galactosidase enzyme activity is the most promising therapy for delaying symptom onset, reducing storage in the brain and peripheral tissues, and increasing lifespan. These impressive results have provided the foundation for AAV gene therapy clinical trials. One of the major challenges for developing treatments for GM1-gangliosidosis is the difficulty in the evaluation of treatment efficacy due to the small and heterogeneous patient population as well as slow progression in non-infantile patients. Recently we used liquid chromatography-tandem mass spectrometry (LC-MS/MS) to identify a pentasaccharide (referred to as H3N2b) that is elevated > 20-fold in patient urine, plasma, and cerebrospinal fluid (CSF), and in the central nervous system (CNS) of the GM1-gangliosidosis cat. The CNS H3N2b levels in the GM1-gangliosidosis cat are reduced in response to AAV-treatment. H3N2b has potential as a pharmacodynamics/response biomarker for assessment of AAV-treatment efficacy in GM1-gangliosidosis. The goal of this proposal is to validate LC-MS/MS methods for determination of H3N2b in human urine, plasma, CSF, which will be used to assess AAV gene therapy treatment efficacy in a clinical trial. The aims of this application are 1) validation of LC-MS/MS methods for quantification of H3N2b in human plasma, urine, and CSF; 2) assessment of H3N2b in samples collected from GM1-gangliosidosis natural history study; and 3) application of H3N2b for assessment of treatment efficacy of AAV gene therapy. The proposed work will provide a much-needed tool for assessing therapeutic efficacy.